SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for IBI363, a first-in-class PD-1/IL-2?-bias bispecific antibody fusion protein, as monotherapy for the treatment of unresectable locally advanced or metastatic mucosal or acral melanoma who have not received prior systemic therapy.
2025
Could AI help diagnose skin cancer?
A new trial program in regional Victoria is working with artificial technology to fast-track skin cancer diagnosis.
Neoadjuvant Pembrolizumab Is Safe and Effective in Resectable Stage III/IV Melanoma
Single-dose neoadjuvant pembrolizumab was safe with no surgical delays and boosted MPR rates in resectable melanoma.
How Cancer Cells Travel to New Tissues and Take Hold
Back in 2014, a woman with advanced cancer pushed Adrienne Boire’s scientific life in a whole new direction. The cancer, which had begun in the breast, had found its way into the patient’s spinal fluid, rendering the middle-aged mother of two unable to walk. “When did this happen?” she asked from her hospital bed. “Why are the cells growing there?”